Reuters logo
BRIEF-BioPharmX receives concurrence from FDA on phase 3 acne study plans
November 8, 2017 / 2:20 PM / a month ago

BRIEF-BioPharmX receives concurrence from FDA on phase 3 acne study plans

Nov 8 (Reuters) - BioPharmX Corp

* BioPharmX Corp receives concurrence from fda on phase 3 acne study plans

* BioPharmX Corp - ‍received positive feedback from u.s. Fda regarding design of co’s planned phase 3 clinical trial for bpx-01

* BioPharmX Corp - ‍company is considering strategic partnering alternatives to fund its phase 3 acne clinical trials​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below